Combinations of beta-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection

We report here a dehydropeptidase-deficient murine model of tuberculosis (TB) infection that is able to partially uncover the efficacy of marketed broad-spectrum beta-lactam antibiotics alone and in combination. Reductions of up to 2 log CFU in the lungs of TB-infected mice after 8 days of treatment compared to untreated controls were obtained at blood drug concentrations and time above the MIC (T->MIC) below clinically achievable levels in humans. These findings provide evidence supporting the potential of beta-lactams as safe and mycobactericidal components of new combination regimens against TB with or without resistance to currently used drugs.


Published in:
Antimicrobial Agents And Chemotherapy, 59, 8, 4997-4999
Year:
2015
Publisher:
Washington, American Society for Microbiology
ISSN:
0066-4804
Laboratories:




 Record created 2015-12-02, last modified 2018-03-17


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)